COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00616434
Recruitment Status : Completed
First Posted : February 15, 2008
Results First Posted : August 13, 2014
Last Update Posted : August 13, 2014
Information provided by (Responsible Party):

Brief Summary:
The primary objective of the study is to evaluate the clinical activity of interferon beta-1a in participants with moderate to severe ulcerative colitis (UC). Secondary objectives of this study are to determine (i) the safety and tolerability of interferon beta-1a in participants with moderate to severe UC, and (ii) the percentage of participants, with a decrease in the Simple Clinical Colitis Activity Index (SCCAI) score of ≥3 points at Week 8.

Condition or disease Intervention/treatment Phase
Active Ulcerative Colitis Drug: BG9418 (Interferon beta-1a) Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 123 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Avonex® in Subjects With Moderate to Severe Ulcerative Colitis
Study Start Date : May 2008
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Interferon beta-1a
Interferon beta-1a 30 µg intramuscular (IM) injection twice weekly for 12 weeks
Drug: BG9418 (Interferon beta-1a)
Avonex IM injection, self-administered per protocol
Other Name: Avonex®

Placebo Comparator: Placebo
Placebo IM injection twice weekly for 12 weeks
Drug: Placebo
Placebo IM injection, self-administered per protocol.

Primary Outcome Measures :
  1. Percentage of Participants With a Clinical Response [ Time Frame: Baseline and Week 8 ]
    Clinical response is defined as a decrease from baseline in the total Mayo score of at least 3 points and at least 30%, accompanied by a decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore of 1 or less. Baseline was defined as the score collected during the screening period. The Mayo Score/Disease Activity Index (DAI) measures disease activity through assessment of 4 items: stool frequency, rectal bleeding, endoscopy findings, and Physician Global Assessment (PGA). Each item of the score is assessed on a 4-point scale, 0, 1, 2, or 3, with a higher score representing greater severity. In this study, the endoscopy subscore was expanded to a 5-point scale to increase sensitivity in this important dimension of the disease (0=normal/inactive disease, 4=deep ulceration). The Total Mayo Score can therefore range from 0 to13 points.

Secondary Outcome Measures :
  1. Number of Participants With Adverse Events (AEs) [ Time Frame: Up to 16 weeks ]
    An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE, can therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AE's were analyzed based on the principle of treatment emergence. An AE was regarded as treatment-emergent if it was not present prior to receiving the first injection but subsequently appeared, or if it was present prior to receiving the first injection and subsequently worsened in severity.

  2. Percentage of Participants With a Decrease on Simple Clinical Colitis Activity Index (SCCAI) of ≥3 Points at Week 8 [ Time Frame: Baseline and Week 8 ]
    The SCCAI measures disease activity as defined by both participants and examiners and includes the following 13 items: general well-being, abdominal pain, bowel frequency, stool consistency, bleeding, anorexia, nausea or vomiting, abdominal tenderness, extra-intestinal complications (eye, mouth, joint, skin), temperature, sigmoidoscopic assessment, nocturnal bowel movements, and urgency of defecation. Scores range from 0 to 19 points, and scores <2.5 have been shown to correlate with Patient-Defined Remission, and a decrease of >1.5 points from Baseline correlates with Patient-Defined Significant Improvement. Baseline is defined as the mean of the screening and visit 1 scores.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Established diagnosis of ulcerative colitis (UC) for ≥6 months

    • 20 cm active disease at Screening endoscopy
  • Must have active UC with a Mayo Score/Disease Activity Index (DAI) of 6 to 13 points and moderate to severe disease on endoscopy (Mayo endoscopic score of at least 2) despite prior or concomitant treatment
  • Colonoscopy within past 5 years for extent of disease and to exclude polyps
  • For subjects with UC for more than 10 years, colonoscopy with appropriate biopsies within 1 year prior to Screening to exclude dysplasia and neoplasia.
  • Must be willing and able to practice effective birth control during the study and for 1 month after the last dose of study treatment.

Key Exclusion Criteria:

  • Diagnosis of indeterminate colitis or Crohn's disease
  • Need for imminent surgery
  • Diagnosis of primary sclerosing cholangitis or toxic megacolon
  • Hemoglobin ≤9 g/dL
  • White blood cell count < 3500 cells/mm^3
  • Lymphocyte count <1000 cells/µL
  • Platelet count <100,000 cells/µL
  • Female subjects who are pregnant or who wish to become pregnant during the study, or who are lactating
  • Known symptomatic colonic stricture
  • Stool cultures positive for enteric infection
  • History of malignant disease
  • History of major abdominal surgery (e.g., gastrectomy) within past 5 years
  • History of small bowel or colonic obstruction or resection
  • History of drug or alcohol abuse (as defined by the Investigator) within 2 years prior to Screening
  • Use of anti-diarrheal agents during the screening period
  • Previous participation in this study
  • Previous treatment with interferon beta or other interferon products

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00616434

Layout table for location information
United States, Alabama
Birmingham, Alabama, United States, 35294
United States, Colorado
Lakewood, Colorado, United States, 80215
United States, Connecticut
Bristol, Connecticut, United States, 06010
United States, Massachusetts
Wellesley Hills, Massachusetts, United States, 02481
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73104
Canada, Alberta
Calgary, Alberta, Canada, T2N4N1
Canada, British Columbia
Kelowna, British Columbia, Canada, V1Y 2H4
Canada, Manitoba
Winnipeg, Manitoba, Canada, R3A1R9
Czech Republic
Hradec Kralove, Czech Republic
Ostrava, Czech Republic
Parbudice, Czech Republic
Praha 4, Czech Republic
Praha 7, Czech Republic
Slany, Czech Republic
Teplice, Czech Republic
Budapest, Hungary
Eger, Hungary
Szeged, Hungary
Szekesfehervar, Hungary
Lublin, Poland
Pruszkow, Poland
Sopot, Poland
Torun, Poland
Warszawa, Poland
Wroclaw, Poland
Russian Federation
Kazan, Russian Federation
Krasnodar, Russian Federation
Lipetsk, Russian Federation
Moscow, Russian Federation
Nizhniy Novgorod, Russian Federation
Rostov-on-Don, Russian Federation
Saratov, Russian Federation
St. Petersburg, Russian Federation
Yaroslavl, Russian Federation
Nitra, Slovakia
Trencin, Slovakia
Sponsors and Collaborators
Layout table for investigator information
Study Director: Medical Director Biogen
Layout table for additonal information
Responsible Party: Biogen Identifier: NCT00616434    
Obsolete Identifiers: NCT00750490
Other Study ID Numbers: 108UC201
2007-004867-22 ( EudraCT Number )
First Posted: February 15, 2008    Key Record Dates
Results First Posted: August 13, 2014
Last Update Posted: August 13, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases
Interferon beta-1a
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic